|
Dec 8
|
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
|
|
Dec 8
|
Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
|
|
Dec 8
|
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
|
|
Dec 7
|
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
|
|
Dec 7
|
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
|
|
Dec 7
|
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
|
|
Dec 7
|
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
|
|
Dec 6
|
J&J (JNJ) Announces 2024 and Long-Term Financial Outlook
|
|
Dec 6
|
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
|
|
Dec 5
|
Pfizer’s Weight-Loss Pill Disappointment Is an Opening for Biotech Rivals
|
|
Dec 5
|
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
|
|
Dec 5
|
CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline
|
|
Dec 5
|
J&J's (JNJ) Bladder Cancer Drug Gets FDA's Breakthrough Tag
|
|
Dec 5
|
Novo Nordisk seeks to use obesity drug findings to prevent weight gain
|
|
Dec 4
|
8 Forces That Shaped 2023—in Charts
|
|
Dec 4
|
Centene (CNC) Wins Contract From Arizona's Medicaid Agency
|
|
Dec 4
|
Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
|
|
Dec 4
|
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
|
|
Dec 4
|
Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It’s Hoping to Compete with Eli Lilly, Novo Nordisk.
|
|
Dec 4
|
Pfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II
|